SCHEMBL464768

SCHEMBL464768

ClCCn1cccn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7350459 0.91 DAO (0.37)
SCHEMBL1426071 0.86
Hydrochloric Acid SCHEMBL3789712 0.84 GAA (0.40)
SCHEMBL5713341 0.84 DAO (0.50)
SCHEMBL9528310 0.82 GAA (0.39)
SCHEMBL7100687 0.79 DAO (0.43)
SCHEMBL869314 0.79
SCHEMBL33257 0.77
Hydrochloric Acid SCHEMBL2186150 0.77
Hydrochloric Acid SCHEMBL2185623 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102153558-B Derivative of multi-target antitumor inhibitor 2-aminopyrrole-triazine and synthesis method thereof YANGZHOU YONGJI MEDICAL NEW TECHNOLOGY CO LTD 2012-11-21 CN claimed
CN-102153558-A Derivative of multi-target antitumor inhibitor 2-aminopyrrole-triazine and synthesis method thereof YANGZHOU YONGJI MEDICAL NEW TECHNOLOGY CO LTD 2011-08-17 CN claimed
US-20260137706-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS INC (US) 2026-05-21 US disclosed
EP-4724440-A1 METHODS OF TREATING INFLAMMATORY DISEASES Interline Therapeutics, Inc. (US) 2026-04-15 EP disclosed
EP-4695241-A1 THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF Danatlas Pharmaceuticals Co., Ltd. (CN) 2026-02-18 EP disclosed
US-20260034113-A1 THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF DANATLAS PHARMACEUTICALS CO LTD (CN) 2026-02-05 US disclosed
EP-4619397-A1 SALT-INDUCIBLE KINASES (SIK) INHIBITORS AND METHODS OF USES THEREOF Insilico Medicine IP Limited (HK) 2025-09-24 EP disclosed
WO-2024254539-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS, INC. (US) 2024-12-12 WO disclosed
CN-113299958-B Proton exchange membrane of fuel cell and preparation method thereof 中国科学院上海有机化学研究所 2024-10-22 CN disclosed
WO-2024213082-A1 THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF DANATLAS PHARMACEUTICALS CO., LTD. (CN) 2024-10-17 WO disclosed
WO-2023154344-A1 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-08-17 WO disclosed
EP-1337524-A1 SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS AstraZeneca AB (SE) 2003-08-27 EP disclosed
CN-1387531-A Pyrazolo [4, 3-d ] pyrimidine derivatives PFIZER LTD (US) 2002-12-25 CN disclosed
CN-1361765-A Aspartyl protease inhibitors VERTEX PHARMA (US) 2002-07-31 CN disclosed
EP-1220856-A2 PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES Pfizer Limited (GB) 2002-07-10 EP disclosed
WO-2002044166-A1 SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2002-06-06 WO disclosed
EP-1194404-A1 INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 2002-04-10 EP disclosed
WO-2001027113-A2 PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES PFIZER LIMITED (GB) 2001-04-19 WO disclosed
WO-2000076961-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2000-12-21 WO disclosed
CN-1253561-A Pyrazolopyrimidinones inhibiting type 5 cyclic guanosine 3',5' -monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction PFIZER LTD (US) 2000-05-17 CN disclosed